Online first
Review paper
Published online: 2023-10-02

open access

Page views 323
Article views/downloads 143
Get Citation

Connect on Social Media

Connect on Social Media

Sotorasib for non-small cell lung cancer — current options and perspectives

Magdalena Knetki-Wróblewska1, Bartosz Wasąg23

Abstract

KRAS regulates several cellular processes, such as cell proliferation, cell cycle regulation, metabolic changes, cell survival, and cell differentiation. Abnormalities in the KRAS gene are found in approximately 30% of patients with non-small cell lung cancer, usually in patients diagnosed with nonsquamous cancer and more often in Caucasian patients, women, and smokers. The p.G12C variant is most frequently found in KRAS-positive patients. Sotorasib is the first drug approved for this population. The superiority of sotorasib over docetaxel after failure of immunochemotherapy was demonstrated in the CodeBreak 200 phase III study for the primary endpoint — median progression-free survival was 5.6 months [95% confidence interval (CI) 4.3–7.8] vs. 4.5 months (3.0–5.7); hazard ratio = 0.66 (95% CI 0.51–0.86; p = 0–0017), while the 12-month progression-free survival rate was 24.8% for sotorasib and 10.1% for docetaxel. Currently, sotorasib monotherapy, at an initial dose of 960 mg/day, is indicated for use in adults with advanced non-small cell lung cancer with the KRAS p.G12C mutation who have experienced disease progression after at least one previous line of systemic treatment. More randomized trials are needed to determine the optimal place of sotorasib in the systemic treatment sequence in this patient population.

Article available in PDF format

View PDF Download PDF file

References

  1. Hendriks LE, Kerr KM, Menis J, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023; 34(4): 339–357.
  2. Hendriks LE, Kerr KM, Menis J, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023; 34(4): 358–376.
  3. Reck M, Carbone DP, Garassino M, et al. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches. Ann Oncol. 2021; 32(9): 1101–1110.
  4. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-sotorasib-kras-g12c-mutated-nsclc.
  5. https://www.ema.europa.eu/en/documents/product-information/lumykras-epar-product-information_en.pdf.
  6. Chang EH, Gonda MA, Ellis RW, et al. Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses. Proc Natl Acad Sci U S A. 1982; 79(16): 4848–4852.
  7. Tsai FD, Lopes MS, Zhou Mo, et al. K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif. Proc Natl Acad Sci U S A. 2015; 112(3): 779–784.
  8. Zhou Y, Hancock JF. Ras nanoclusters: Versatile lipid-based signaling platforms. Biochim Biophys Acta. 2015; 1853(4): 841–849.
  9. Wittinghofer A, Vetter IR. Structure-function relationships of the G domain, a canonical switch motif. Annu Rev Biochem. 2011; 80: 943–971.
  10. Welman A, Burger MM, Hagmann J. Structure and function of the C-terminal hypervariable region of K-Ras4B in plasma membrane targetting and transformation. Oncogene. 2000; 19(40): 4582–4591.
  11. Abraham SJ, Muhamed I, Nolet R, et al. Expression, purification, and characterization of soluble K-Ras4B for structural analysis. Protein Expr Purif. 2010; 73(2): 125–131.
  12. Singh K, Groth-Vasselli B, Farnsworth PN, et al. Effect of thiobase incorporation into duplex DNA during the polymerization reaction. Res Commun Mol Pathol Pharmacol. 1996; 94(2): 129–140.
  13. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer. 2003; 3(6): 459–465.
  14. Prior IA, Hood FE, Hartley JL. The Frequency of Ras Mutations in Cancer. Cancer Res. 2020; 80(14): 2969–2974.
  15. Dogan S, Shen R, Ang DC, et al. Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin Cancer Res. 2012; 18(22): 6169–6177.
  16. Ellis RW, Defeo D, Shih TY, et al. The p21 src genes of Harvey and Kirsten sarcoma viruses originate from divergent members of a family of normal vertebrate genes. Nature. 1981; 292(5823): 506–511.
  17. Wood K, Hensing T, Malik R, et al. Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review. JAMA Oncol. 2016; 2(6): 805–812.
  18. Martin P, Leighl NB, Tsao MS, et al. KRAS mutations as prognostic and predictive markers in non-small cell lung cancer. J Thorac Oncol. 2013; 8(5): 530–542.
  19. Skoulidis F, Heymach JV. Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy. Nat Rev Cancer. 2019; 19(9): 495–509.
  20. Della Corte CM, Morgillo F. Rethinking treatment for RET-altered lung and thyroid cancers: selpercatinib approval by the EMA. ESMO Open. 2021; 6(1): 100041.
  21. Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020; 31(11): 1491–1505.
  22. Wolff HB, Steeghs EMP, Mfumbilwa ZA, et al. Cost-Effectiveness of Parallel Versus Sequential Testing of Genetic Aberrations for Stage IV Non-Small-Cell Lung Cancer in the Netherlands. JCO Precis Oncol. 2022; 6: e2200201.
  23. Steeghs EMP, Groen HJM, Schuuring Ed, et al. PATH consortium. Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice. Lung Cancer. 2022; 167: 87–97.
  24. Dall'Olio FG, Conci N, Rossi G, et al. Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients - A single centre experience. Lung Cancer. 2020; 149: 5–9.
  25. Kuang S, Fung AS, Perdrizet KA, et al. Upfront Next Generation Sequencing in Non-Small Cell Lung Cancer. Curr Oncol. 2022; 29(7): 4428–4437.
  26. A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100). ClinicalTrials.gov.
  27. Skoulidis F, Li BT, Dy GK, et al. Sotorasib for Lung Cancers with p.G12C Mutation. N Engl J Med. 2021; 384(25): 2371–2381.
  28. Dy GK, Govindan R, Velcheti V, et al. Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100. J Clin Oncol. 2023; 41(18): 3311–3317.
  29. de Langen AJ, Johnson ML, Mazieres J, et al. CodeBreaK 200 Investigators. Sotorasib versus docetaxel for previously treated non-small-cell lung cancer with KRAS mutation: a randomised, open-label, phase 3 trial. Lancet. 2023; 401(10378): 733–746.
  30. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(2): 123–135.
  31. Rittmeyer A, Barlesi F, Waterkamp D, et al. OAK Study Group. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017; 389(10066): 255–265.
  32. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016; 387(10027): 1540–1550.
  33. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17): 1627–1639.
  34. Awad M, Pelizzari G, Stevenson JP, et al. 989P Sotorasib in advanced KRAS p.G12C-mutated non-small cell lung cancer (NSCLC): Safety and efficacy data from the global expanded access program (EAP). Ann Oncol. 2022; 33: S1005.
  35. Novello S, Maimon N, Stevenson JP, et al. 7MO Sotorasib in KRAS G12C-mutated advanced non-small cell lung cancer (aNSCLC): Overall survival (OS) data from the global expanded access program (EAP study-436). J Thorac Oncol. 2023; 18(4): S40–S41.
  36. Cadranel J, Quantin X, Girard N, et al. 1121P Real-world (RW) data from the sotorasib French pre-market authorization early access program in patients (pts) with KRASG12C driven metastatic non-small cell lung cancer (mNSCLC): Clinical characteristics. Ann Oncol. 2022; 33: S1063–S1064.
  37. Thummalapalli R, Bernstein E, Herzberg B, et al. Clinical and Genomic Features of Response and Toxicity to Sotorasib in a Real-World Cohort of Patients With Advanced -Mutant Non-Small Cell Lung Cancer. JCO Precis Oncol. 2023; 7: e2300030.
  38. Negrao MV, Araujo HA, Lamberti G, et al. Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC. Cancer Discov. 2023; 13(7): 1556–1571.
  39. https://www.ema.europa.eu/en/documents/product-information/lumykras-epar-product-information_pl.pdf.
  40. Chmielewska I, Krawczyk P, Grenda A, et al. Breaking the 'Undruggable' Barrier: Anti-PD-1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer Patients with Mutations-A Comprehensive Review and Description of Single Site Experience. Cancers (Basel). 2023; 15(14).
  41. Knetki-Wróblewska M, Tabor S, Płużański A, et al. Efficacy of Immunotherapy in Second-Line Treatment of -Mutated Patients with Non-Small-Cell Lung Cancer-Data from Daily Practice. Curr Oncol. 2022; 30(1): 462–475.
  42. Landre T, Justeau G, Assié JB, et al. Anti-PD-(L)1 for KRAS-mutant advanced non-small-cell lung cancers: a meta-analysis of randomized-controlled trials. Cancer Immunol Immunother. 2022; 71(3): 719–726.
  43. Guo X, Du He, Li J, et al. Efficacy of ICIs on patients with oncogene-driven non-small cell lung cancer: a retrospective study. Cancer Drug Resist. 2022; 5(1): 15–24.
  44. Mazieres J, Drilon A, Lusque A, et al. Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019; 30(8): 1321–1328.
  45. Nakajima E, Ren Yi, Vallejo J, et al. Outcomes of first-line immune checkpoint inhibitors with or without chemotherapy according to KRAS mutational status and PD-L1 expression in patients with advanced NSCLC: FDA pooled analysis. J Clin Oncol. 2022; 40(16_suppl): 9001–9001.
  46. https://clinicaltrials.gov/study/NCT05920356?cond=nsclc&intr=sotorasib&page=1&rank=4.
  47. https://clinicaltrials.gov/study/NCT04933695?cond=nsclc&intr=sotorasib&page=1&rank=3.
  48. Desai A, Rakshit S, Bansal R, et al. Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report. Cancer Treat Res Commun. 2023; 36: 100743.